Clinical outcomes in individuals hospitalized with SARS-CoV-2 Delta variant (B.1.617.2) who had been vaccinated with Covishield (ChAdOx1) and Covaxin (BBV-152)

BACKGROUND: Covishield (ChAdOx) and Covaxin (BBV-152) are the mainstream vaccines against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) used in India and a few other countries. OBJECTIVE: To assess the clinical outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19)...

Descripción completa

Detalles Bibliográficos
Autores principales: Munigela, Apoorva, Sowpati, Divya Tej, M, Sasikala, Banu, Sofia, Siva, Archana Bharadwaj, V, Jagadeesh Kumar, Nutalapati, Chandrasekhar, Vishnubhotla, Ravikanth, Kulkarni, Anand, Mukherjee, Payel, Zaveri, Lamuk, Rao, G.V., Tallapaka, Karthik Bharadwaj, Nageshwar Reddy, D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Coronavirus (COVID-19) Collection
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444261/
https://www.ncbi.nlm.nih.gov/pubmed/36090517
http://dx.doi.org/10.1016/j.ijregi.2022.08.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444261/
https://www.ncbi.nlm.nih.gov/pubmed/36090517
http://dx.doi.org/10.1016/j.ijregi.2022.08.016

Ejemplares similares